Cigarette Smoking and Dyspnea Perception by Rosi, Elisabetta & Scano, Giorgio
________________________________________ 
Correspondence: G. Scano, MD, Section of Immunoallergology and Respiratory Diseases, Department of Internal Medicine, 
University of Florence, viale G.B. Morgagni 85, 50134 Firenze, Italy 
Email: g.scano@dmi.unifi.it 
Fax: +39-055412867 
 
ABSTRACT: Cigarette smoking has been implicated as an important risk factor for the 
development of respiratory symptoms in adults. The relationship of dyspnea with cigarette 
smoking has been examined in smokers and ex-smokers and the beneficial effects of smok-
ing cessation have been demonstrated. Recent studies reported that in subjects who smoke 
cigarettes the risk of developing respiratory symptoms is higher in a dose-dependent way. 
Environmental tobacco smoke heavily influences the incidence of respiratory symptoms 
in both adults and in children. Up to the present time, the mechanisms whereby cigarette 
smoking causes dyspnea perception remain to be defined. Abnormalities in sensory nerves 
might diminish the perception of bronchoconstriction in smokers. In this regard, it has been 
postulated that prolonged exposure to cigarette smoke may lead to chronic depletion of sen-
sory nerve neurotransmitters. Eosinophil airway inflammation has been proposed as a de-
terminant of breathlessness via mechanisms affecting either the mechanical pathways that 
control breathlessness or the afferent nerves involved in perception of dyspnea. An increased 
number of eosinophils in some smokers implies the possibility that smoking may trigger 
immunological or other reactions associated with eosinophilia. In conclusion, cigarette 
smoking is by far one of the greatest risk factors for most respiratory symptoms, including 
dyspnea. Smoking is associated with the development of symptoms in a dose-dependent way 
and eosinophilia and airway hyperresponsiveness (AHR) increase the risk of developing 
dyspnea. 
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INTRODUCTION 
 
The mechanisms responsible for inter-individual 
differences in dyspnea perception are difficult to clarify 
due to the wide variation in the perception of breath-
lessness present in normal subjects [1] in whom the 
experience of breathlessness may modify subsequent 
estimates of the symptom [2]. In a disease state, it 
may not be possible to identify these inherent inter-
individual differences and this may confound attempts 
to identify the effects due to disease. Mechanical fac-
tors including respiratory muscle activity [3] associated 
with pulmonary hyperinflation [4-6], temporal adapta-
tion [7-9] and bronchial hyperresponsiveness [7], psy-
chological factors [10]
 or emotional and cognitive fac-
tors [11] have been proposed to influence the percep-
tion of dyspnea. Moreover, some recent reports [12-16] 
make a strong case for airway inflammation contribut-
ing to cover a part of the unexplained variability of the 
symptom. 
 
CIGARETTE SMOKING AND 
RESPIRATORY SYMPTOMS 
 
Cigarette smoking has been implicated as an im-
portant risk factor for the development of respiratory 
symptoms in adults [17]. On this topic significant re-
sults have been obtained from the group of Tucson. 
Krzyzanowski and Lebowitz [17] showed that subjects 
who continued to smoke during the 11 to 13 years of 
follow-up ran a two or three times higher risk of devel-
oping respiratory symptoms such as dyspnea and at-
tacks of breathlessness compared with lifetime non-
smokers. Krzyzanowski and Lebowitz [17] examined 
TOBACCO INDUCED DISEASES  Vol. 2, No. 1: 35-42 (2004)  © PTID Society Table 1. Prevalence of development of respiratory symptoms by smoking habits 
From Jansen et al.  (8)   
Ex smoker 
1-14 cig/day 
15-24 cig/day 
>24 cig/day  
OR (respiratory symptoms) 
1.21 
1.89* 
2.98* 
3.57* 
 
From Lindström et al. 
(10) 
 
Nonsmokers 
Ex-smokers 
smokers 
% (Dyspnea grade 3)-Norrbotten 
4.5 (m)   7.7(f)* 
46.7 (m)   12.8(f)* 
10.3 (m)   11.7(f)* 
% (Dyspnea grade 3) Lapland
8.1(m)    17.2(f)* 
18.5 (m)  20.4(f)* 
12.7 (m)    18.2(f)* 
*p<0.001; f: female, m: male 
data from two longitudinal studies conducted in Cra-
cow, Poland, and Tucson, Arizona, to assess the simi-
larities in the relationship of symptoms to age and 
smoking habit in the two cities. The relationship of 
symptoms to smoking was similar in both cities, after 
adjustment for age and gender, with at least doubled 
incidence rates of most symptoms in continuous smok-
ers compared to lifetime non-smokers. Furthermore, the 
same authors [18] investigated the relationship between 
persistence and incidence rates of respiratory symptoms 
and smoking cessation. Among 1,722 subjects smoking 
at the beginning of the study, 468 had given up smok-
ing by the end of the 13-year follow-up. The persistence 
and incidence rate of attacks of breathlessness as well 
as chronic cough, chronic phlegm and wheeze were 
reduced by 50% in ex-smokers compared to those sub-
jects who continued to smoke. The beneficial effects of 
smoking cessation were lower in those subjects who 
had smoked a higher number of cigarettes per day in the 
past and had started smoking younger. The symptoms 
were less likely if smoking ceased before the onset of 
any respiratory disease. These results were similar in 
the Cracow and Tucson populations, suggesting the 
universal nature of the observations [18]. Smokers who 
are able to break the habit generally experience a reduc-
tion in respiratory symptoms and improvement in pul-
monary function; however, gender and particularly age 
are important influencing factors [19,20]. Sherril and 
colleagues [19], analyzing respiratory function and 
symptom data from a follow-up period of up to 20 years 
in Tucson, compared the respiratory status between 
restarters, consistent smokers and ex-smokers. The 
symptoms included any wheeze, cough, dyspnea or 
phlegm. The authors demonstrated that there were no 
statistically significant differences between the initial 
symptoms reported by restarters and consistent smok-
ers. However, consistent smokers did report signifi-
cantly more dyspnea during the last survey. 
Data were similar for male and female subjects. 
The results of the symptom-analysis of both the initial 
and last surveys would suggest that although restarters 
have the steepest rates of decline in FEV1, they have 
fewer symptoms than consistent smokers who reported 
more dyspnea at the last survey [19]. This might arise 
from a reporting bias by subjects who relapsed, being 
less likely to admit symptoms resulting from their in-
ability to quit the habit even if they reported more 
phlegm. The fact that male ex-smokers had more symp-
toms than restarters implicates that this subgroup con-
tains subjects who quit the habit after developing symp-
toms that, for the most part, were irreversible [21]. 
More recently, Jansen and colleagues [22] (see Table1) 
found that cigarette smokers had an increased risk of 
developing respiratory symptoms compared to people 
who had never smoked. They demonstrated, through a 
25-year follow-up study of the general adult population 
from Vlagtwedde and Vlaardingen (The Nederlands), 
that in subjects who smoke cigarettes the risk of devel-
oping respiratory symptoms is higher in a dose-
dependent way. Dyspnea perception was assessed using 
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Council (MRC) standardized questionnaire. Subjects 
were considered symptomatically affected if their re-
ported dyspnea was over grade 3 of the MRC question-
naire. Development of wheeze and dyspnea appeared to 
occur especially in subjects with both airway hyperre-
sponsiveness (AHR) and peripheral blood eosinophilia 
[22]. On the contrary Xu and colleagues [23] have 
shown that the risk of smoking for the development of 
symptoms was the same in AHR+ as in AHR- subjects. 
Lindström and colleagues [24] (see Table 1) performed 
a comparative study between Northern Sweden and 
Northern Finland by analyzing the influence of smok-
ing on the prevalence of respiratory symptoms includ-
ing exertional dyspnea. Their results indicate that the 
prevalence of symptoms is strongly related to the num-
ber of cigarettes smoked per day. Furthermore, they 
observed that bronchitic symptoms were more common 
in Finland, even after the correction of demographic 
variables including smoking habits. According to the 
authors, this difference may be due to air pollution and 
particularly to environmental tobacco smoke (ETS). 
 
DYSPNEA AND ENVIRONMENTAL 
TOBACCO SMOKE 
 
It has been demonstrated that ETS heavily influ-
ences the incidence of respiratory symptoms both in 
adults [25,26] and in children [27]. Jaakkola and col-
leagues [25] examined the relationship between expo-
sure to ETS and development of respiratory symptoms 
including dyspnea, in a population of 117 subjects who 
had never smoked and who were aged between 15 and 
40 at the time of initial examination, and who were re-
examined eight years later. A significant dose-related 
increase in the risk of developing dyspnea was observed 
in connection with ETS exposure. In a recent paper 
Gilliland and colleagues [28] demonstrated that mater-
nal smoking during pregnancy and current ETS expo-
sure were associated with an increased prevalence of 
attacks of wheezing causing shortness of breath in chil-
dren residing in 12 communities in Southern California. 
Jansen and colleagues [22] (see Table 1) recently 
demonstrated that among current smokers the number 
of cigarettes smoked per day was consistently the 
strongest risk factor relative to the development of 
chronic cough, chronic phlegm, wheeze, and dyspnea 
respectively. Schenker and colleagues observed in adult 
women that cigarette particulate content (tar) was sig-
nificantly related to cough and phlegm production, 
while the association between smoking and symptoms 
of wheeze and dyspnea was supposed to be more 
strongly related to the vapor phase of cigarette smoke 
[29]. In a more recent study, after adjustment for inten-
sity and length of smoking history and for depth of in-
halation, the risk of chronic phlegm, cough, and dysp-
nea were not related to the tar and nicotine yields [30].  
Up to the present time, the mechanisms whereby 
cigarette smoking causes dyspnea perception remain to 
be defined. Figure 1 is an attempt to elucidate some 
potential mechanisms (for explanation see below). Ab-
normalities in sensory nerves might diminish the per-
ception of bronchoconstriction in smokers. In this re-
gard, it has been postulated that prolonged exposure to 
cigarette smoke may lead to chronic depletion of sen-
sory nerve neurotransmitters [31]. 
 
CIGARETTE SMOKING AND COPD 
 
Active smoking is certainly the most important 
causative factor of COPD (Figure 1) , even though only 
a proportion of smokers will develop the disease. There 
is consisting evidence of a dose-response relationship 
between the amount of smoking and the decline in 
FEV1 [32]. Regarding the reversion of smoking effect 
on bronchial obstruction, a reduction in the decline of 
FEV1 has been demonstrated, without returning to the 
basal level. [33] 
Smoking habit has a prominent role in the in-
Environmental and 
occupational pollution
Cigarette smoke
Respiratory
infections
Genetic susceptibility
Lung recoil Airway inflammation
and remodelling
Expiratory flow
limitation
Hyperinflation
DYSPNEA
Figure 1. Pathogenetic mechanisms of dyspnea in 
smokers with COPD. Exposure to cigarette smoke is 
the major factor in the pathogenesis of COPD. Risks 
conferred by smoking interact with genetic suscepti-
bility and respiratory infections to produce expira-
tory flow limitation (EFL) by loss of elastic recoil 
and airway inflammation. EFL, by producing hyper-
inflation and hyperinflation per se generate dyspnea 
sensation. 
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COPD and the major symptom of the disease [34]. 
(Figure 1). Despite similar level of bronchoconstriction 
the degree of dyspnea sensation may be widely variable 
in COPD [35,36] as well as in asthmatic patients 
[16,37,38]. Getting insight into these mechanisms, Ot-
tanelli and colleagues [36] have shown that smokers 
with chronic airflow limitation could be either hypoper-
ceivers, moderate perceivers or hyperperceivers to an 
acute change in airway caliber with methacholine. In 39 
patients dyspnea was assessed during a methacholine-
induced FEV1 % fall using a Borg scale. Acute hyperin-
flation accounted in part for the variability in the per-
ception of dyspnea after accounting for change in FEV1 
during bronchoconstriction. (Figure 2). In that, Ottanelli 
and colleagues [36], in line with previous data [35,37], 
have identified some potential factors for increasing the 
prediction of the variation in breathlessness after ac-
counting for FEV1 decrease. The increase in end expira-
tory lung volume on the one hand increases the central 
output to the respiratory muscles and on the other de-
creases their maximal capacity of generating inspiratory 
pressure. That increases the sense of inspiratory effort, 
that is, breathlessness. Furthermore, because of the 
bronchoconstriction and expiratory flow limitation, the 
increased respiratory drive does not result in a propor-
tional increase in tidal volume or inspiratory flow. This 
is another potential mechanism of dyspnea [34]. As 
shown in Figure 3, for a given tidal volume a greater 
inspiratory effort is needed in smokers with airflow 
limitation as compared to healthy subjects, such that the 
greater the slope (b) of VT to effort relationship, the 
greater the perception of dyspnea. Figure 3 also shows 
the increase in the intercept (a) of this relationship, 
which defines the increase in end expiratory lung vol-
ume (hyperinflation). Thus, both a and b result in an 
increased dyspnea sensation.  
 
CIGARETTE SMOKING AND 
AIRWAY INFLAMMATION 
 
Neutrophilic airway inflammation and release of 
neutrophil chemoattractant cytokines, including IL-8, 
have been observed to be associated with smoke expo-
sure, with sputum IL-8 concentration being related to 
percent-predicted forced expiratory volume in 1 second 
(FEV1) in smoking asthmatics [39]. However, the influ-
ence of neutrophilic airway inflammation on respiratory 
symptoms has not yet been determined [39,40]. On the 
other hand, eosinophil airway inflammation has been 
proposed as a determinant of breathlessness [41-43] via 
mechanisms affecting either the mechanical pathways 
that control breathlessness [44,45] or the afferent nerves 
involved in perception of dyspnea [16,41]. Ottanelli and 
colleagues [16] have shown that eosinophilic inflamma-
tion of the airway wall may affect the perception of 
dyspnea positively and that the association of eosino-
phils with inhaled corticosteroids may result in the per-
ception of dyspnea in asthma getting worse (Figure 4). 
Two cases of acute eosinophilic pneumonia associated 
with cigarette smoking, after excluding any other iden-
tifiable cause, have recently been reported [46]. 
Mensinga and colleagues [47] examined the independ-
ent and combined effect of skin test reactivity and eosi-
nophilia on the prevalence of a variety of respiratory 
symptoms, after adjusting for age, sex, smoking habit, 
and area of residence. Subjects with eosinophilia were 
more likely to be symptomatic than subjects without 
eosinophilia with the exception of male subjects who 
never smoked [47]. The total number of leukocytes may 
be increased by cigarette smoking [48]. One of the 
components of the leukocyte count is formed by the 
overall number of eosinophils. An increased number of 
eosinophils in some smokers implies the possibility that 
smoking may trigger immunological or other reactions 
Figure 2. Relationship between change (∆) in
inspiratory capacity (IC) and slope of Borg score on
FEV1% fall during methacholine-induced broncho-
constriction. Symbols indicate: square – hypoper-
ceivers;  triangles – normoperceivers; circles – hy-
perperceivers. (Reproduced with permission from
reference [36].) For explanation see text. 
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and colleagues [22] demonstrated that peripheral blood 
eosinophilia increased the risk of developing dyspnea 
independent of smoking in the general adult population. 
The presence of respiratory symptoms has been 
examined as a marker of susceptibility to the detrimen-
tal effect of smoking on respiratory function. In an 
analysis from the Tucson study of data on the growth of 
pulmonary function between 5.5 and 25 years of age, 
symptoms and smoking had a negative impact on 
growth of lung function, using FVC, FEV1, Vmax50, 
and size-compensated flows (Vmax50/FVC). Smoking 
cessation was shown to have a positive impact on 
growth of pulmonary function. Young smokers without 
respiratory symptoms experienced the same longitudi-
nal changes in FEV1 as non-smokers [50]. 
Interestingly, the habit of smoking may influence 
dyspnea perception also in fibrotic diseases. De Cre-
moux and colleagues [51] examined two populations of 
patients with idiopathic pulmonary fibrosis: non-
smokers versus smokers. Despite similar pulmonary 
function test results, non-smokers had a shorter duration 
of symptoms at the time of presentation than smokers. 
Prednisolone therapy was more efficient in non-
smokers than in smokers. 
In summary, cigarette smoking is by far one of 
the greatest risk factors for most respiratory symptoms, 
including dyspnea. Smoking is associated with the de-
velopment of symptoms in a dose-dependent way and 
eosinophilia and AHR increase the risk of developing 
dyspnea. In short, further studies are necessary in order 
to establish the exact interaction between cigarette 
smoking and airway inflammation with dyspnea per-
ception. 
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